厄洛替尼与标准一线化疗作为新辅助治疗ⅢA-N2期EGFR突变阳性非小细胞肺癌患者的疗效比较
Erlotinib Versus Standard First-Line Chemotherapy as Neoadjuvant Treatment for Stage ⅢA-N2 EGFR-Mutation Positive Non-Small Cell Lung Cancer
厄洛替尼与标准一线化疗作为新辅助治疗ⅢA-N2期EGFR突变阳性非小细胞肺癌患者的疗效比较 |
|
评价者：康晓征 |
Erlotinib Versus Standard First-Line Chemotherapy as Neoadjuvant Treatment for Stage ⅢA-N2 EGFR-Mutation Positive Non-Small Cell Lung Cancer |
| |